PVALB and Parkinson disease: For example, activating PV neurons in the substantia nigra can restore motor function in Parkinson's disease models [26], and in a mouse model of cerebellar dystonia, activation of striatal parvalbumin interneurons, combined D1 receptor agonist and D2 receptor antagonist administration and selective ablation of striatal PV interneurons all alleviated involuntary movements [30].